DV Equities’s Bristol-Myers Squibb BMY Stock Holding History

DV Equities’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	$153K	Buy	+2,839	New	+$137K	0.03%	165

Other funds holding BMY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

DV Equities's BMY Position: Q4 2025 in Review

DV Equities opened a new position in Bristol-Myers Squibb (BMY) in Q4 2025: 2,839 shares worth $153K. The stake represents 0.03% of the portfolio and ranks #165 among its holdings.

2,461 funds tracked by Wall St. Rank hold BMY as of Q4 2025.

DV Equities held 2,839 shares of Bristol-Myers Squibb worth $153K as of Q4 2025.
Bristol-Myers Squibb was a new DV Equities position in Q4 2025.
Bristol-Myers Squibb made up 0.03% of DV Equities's portfolio in Q4 2025, its #165 holding.
2,461 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q4 2025.

Based on DV Equities's 13F filing for Q4 2025, filed 17 Feb 2026.